Daniel G Welch has sold stock and made no open-market buys since Jul 2017

Daniel G. Welch is a person and a veteran biotechnology and pharmaceutical executive who has served in senior operating, board, and advisory roles across the life sciences sector.( He recently served as a director of Seagen Inc. until its acquisition by Pfizer in December 2023, and he currently serves on several biotechnology boards, including as chair of boards such as Ultragenyx Pharmaceuticals, Nuvation Bio, and Structure Therapeutics.(

Welch’s career includes leadership roles as CEO and president of InterMune, chair and CEO of Triangle Pharmaceuticals, and president of the pharmaceutical division of Elan Corporation; he also served as an executive partner at Sofinnova Ventures.( He has over 30 years of experience in drug development and commercialization, with board and executive involvement in multiple companies that developed therapies for cancer, rare diseases, cardiovascular disease, HIV, and multiple sclerosis.( Welch earned a B.A./B.S. from the University of Miami and an M.B.A. from the University of North Carolina.(

Written by Perplexity from public sources.